2型糖尿病患者中无创指标诊断NASH及进展性纤维化的性能
该横断面研究纳入213例2型糖尿病患者,评估多种无创临床模型及血浆生物标志物诊断NASH和进展性纤维化的性能。结果显示诊断NASH的所有工具AUC均<0.80,未优于ALT;诊断进展性纤维化以PRO-C3、AST和APRI表现较好,但均未显著优于AST。
要点
- 在2型糖尿病患者中,无创工具诊断NASH性能欠佳,AUC均<0.80。
- 诊断进展性纤维化时,PRO-C3、AST和APRI的AUC较高。
- 联合AST与其他无创检测可能减少肝活检需求。
核心结论
- 无创临床模型及血浆生物标志物诊断2型糖尿病患者NASH或进展性纤维化的性能均不理想。
研究设计与样本
- 横断面研究,纳入213例2型糖尿病患者,先进行肝脏MRS,诊断为NAFLD者接受经皮肝活检。
主要发现
- 诊断NASH的所有无创工具AUC均<0.80,无一优于ALT(AUC 0.78,95%CI 0.71-0.84)。
- 诊断进展性纤维化时,PRO-C3的AUC为0.90(95%CI 0.85-0.95),AST为0.85(95%CI 0.80-0.91),APRI为0.86(95%CI 0.80-0.91)。
- 诊断进展性纤维化时,没有无创方法显著优于血浆AST。
关键数值与推荐
- NASH诊断工具包括ALT、细胞角蛋白-18、NashTest 2、HAIR、BARD和OWLiver。
- 进展性纤维化诊断工具包括AST、PRO-C3、FIB-4、APRI、NAFLD纤维化评分和FibroTest。
临床怎么用
- 在2型糖尿病患者中,可考虑联合使用血浆AST与其他无创检测来识别进展性纤维化,以减少肝活检需求。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: The 2019 Standards of Medical Care in Diabetes suggested that patients with nonalcoholic fatty liver disease (NAFLD) should be evaluated for liver fibrosis. However, the performance of noninvasive clinical models/scores and plasma biomarkers for the diagnosis of nonalcoholic steatohepatitis (NASH) and advanced fibrosis has not been carefully assessed in patients with type 2 diabetes mellitus (T2DM). RESEARCH DESIGN AND METHODS: In this cross-sectional study, patients (n = 213) had a liver MRS, and those with a diagnosis of NAFLD underwent a percutaneous liver biopsy. Several noninvasive clinical models/scores and plasma biomarkers were measured to identify NASH and advanced fibrosis (NASH: ALT, cytokeratin-18, NashTest 2, HAIR, BARD, and OWLiver; advanced fibrosis: AST, fragments of propeptide of type III procollagen [PRO-C3], FIB-4, APRI, NAFLD fibrosis score, and FibroTest). RESULTS: None of the noninvasive tools assessed for the diagnosis of NASH in patients with T2DM had an optimum performance (all areas under the curve [AUCs] <0.80). Of note, none of the panels or biomarkers was able to outperform plasma ALT (AUC 0.78 [95% CI 0.71-0.84]). Performance was better to diagnose advanced fibrosis, in which plasma PRO-C3, AST, and APRI showed better results than the other approaches (AUC 0.90 [0.85-0.95], 0.85 [0.80-0.91], and 0.86 [0.80-0.91], respectively). Again, none of the approaches did significantly better than plasma AST. Sequential use of plasma AST and other noninvasive tests may help in limiting the number of liver biopsies required to identify patients with advanced fibrosis. CONCLUSIONS: Performance of noninvasive clinical models/scores and plasma biomarkers for the diagnosis of NASH or advanced fibrosis was suboptimal in patients with T2DM. Combination of multiple tests may provide an alternative to minimize the need for liver biopsies to detect fibrosis in these patients.
引用
- Bril F, McPhaul MJ, Caulfield MP, et al. Performance of Plasma Biomarkers and Diagnostic Panels for Nonalcoholic Steatohepatitis and Advanced Fibrosis in Patients With Type 2 Diabetes. Diabetes Care. 2019. PMID: 31604692. doi:10.2337/dc19-1071
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。